Immuneel Therapeutics Pvt. Ltd.

Immuneel at the 4th Series on Advancements in Cell Therapy – An Asia Pacific Cell Therapy Conference We were honoured to contribute to the 4th Series on Advancements in Cell Therapy, hosted by Tata Memorial Centre, Mumbai, where leading voices in cell and gene therapy (CGT) across the Asia-Pacific region gathered to drive progress in the field. At Immuneel, our commitment to advancing affordable, high-quality, and accessible cell therapies for patients in India and beyond aligns with the core themes of the conference. Our leadership team engaged in pivotal discussions across key tracks: 1.     Commercialisation Track: Mr. Amit Mookim, CEO, shared insights as a panellist on making cell therapy sustainable and scalable while maintaining global quality standards. 2.     Manufacturing & CMC Track: Dr. Lakshmikanth Gandikota, Head of R&D, chaired the session, highlighting how CMC strategies can drive efficiency and reliability in cell therapy manufacturing. 3.     Regulatory Panel Discussion: Mr. Yogananth Rajendran, Head of RA and QA, moderated a thought-provoking discussion on balancing regulatory compliance with innovation, enabling smoother clinical-to-commercial transitions. These discussions reinforce the need for collaboration between academia, industry, and regulatory bodies to unlock the full potential of CGT in Asia-Pacific. We are proud to be part of this ecosystem, working towards affordable, accessible, and cutting-edge cancer care. We appreciate Tata Memorial Centre for organizing this impactful forum! #Immuneel #CellTherapy #CGT #Innovation #RegulatoryScience #Manufacturing #Healthcare #India #AsiaPacific #TataMemorialCentre #AffordableTherapies Amit Mookim Lakshmikanth Gandikota Yogananth Rajendran M.Pharm.RAC Bruce Levine Swapnil Waichale

Immuneel Therapeutics Pvt. Ltd. Finalist under the Innovation in Health category at the prestigious Aegis Graham Bell Award! This recognition is a testament to our relentless commitment to advancing cutting-edge cell and gene therapies, making innovative cancer care more accessible and affordable. Melina Soares Lakshmikanth Gandikota Amit Mookim Akhil Agarwal

Immuneel Therapeutics is proud to have participated in the Essence of ASH conference in Mumbai today, where advancements in hematology took center stage. Dr. Sharat Damodar, Head of Adult Hemato-Oncology at Narayana Health, moderated an impactful panel discussion on the Indian experience with CAR T cell therapies. The panel featured esteemed hemato-oncologists Dr. Prashant Mehta, Dr. Sameer Melinkeri, Dr. Nikita Mehra, and Dr. Sanket Shah, who shared their valuable insights on the journey of CAR T in India, including its challenges, successes, and potential to redefine patient outcomes. A highlight of the session was a keynote by Dr. Alvaro Urbano from Hospital Clinic de Barcelona, who shared his extensive experience with Varnimcabtagene autoleucel (Qartemi) and other CAR T cell therapies. His expertise brought a global perspective to the discussion, inspiring new possibilities for CAR T therapies in emerging markets. At Immuneel, we are committed to advancing innovative cell and gene therapies for patients in India and beyond. Today's discussions reaffirm our belief in the transformative potential of CAR T therapies to address unmet needs in hematological malignancies. Together, we move closer to making cutting-edge therapies accessible to patients everywhere. #EssenceOfASH #CellTherapy #CART #cartcelltherapy Amit Mookim Anupam Chhabra, MD, MBA Noelia Mateo Akhil Agarwal Rebu Ninan

Immuneel is bridging the gap in advanced cancer care. Qartemi represents a transformative step for patients facing unmet medical needs. https://lnkd.in/gjyFEqWT Amit Mookim #cellandgenetherapy #cartcelltherapy #canctreatment #innovation

A Proud Moment at Bengaluru Tech Summit 2024 as Dr. Kiran Mazumdar Shaw graced the inaugural ceremony alongside the Chief Minister of Karnataka and other distinguished luminaries! We are delighted to share that Dr. Lakshmikanth Gandikota, our Head of Research and Development, MSAT, Intellectual Property, and Translational Research, had the incredible opportunity to participate in the panel discussion on "Next-Gen Immunotherapies for Cancer" at the prestigious Bengaluru Tech Summit 2024. It was an honour to share the stage with some of the most visionary minds in the field: Dr. Jyothsna Rao, Research Director, International Stem Cell Services Dr. Kavitha Iyer Rodrigues, CEO, Zumutor Biologics Dr. Ujjwal Rao, CEO, Rector Healthcare Keynote Speaker: Dr. Claire Mazumdar, CEO, Bicara Therapeutics Moderator: Dr. Vishal Rao, Director, HCG Cancer Centre The session highlighted cutting-edge advancements in immunotherapy, collaborative innovation, and the shared commitment to revolutionizing cancer treatment. Our Head of R&D brought unique insights into CAR T-cell therapy development, sparking meaningful dialogue with fellow experts and attendees. We thank the organizers and our esteemed co-panelists for this enriching experience. Let’s continue pushing the boundaries of what’s possible in the fight against cancer! Lakshmikanth Gandikota Amit Mookim #BengaluruTechSummit2024 #InnovationInCancerCare #Immunotherapy #CellAndGeneTherapy 

At Haematocon 2024, held in Nagpur from November 7th to 10th, we witnessed engaging discussions and scientific advancements in haemato-oncology. One of the highlights was Dr. Sharat Damodar, Chairman of Oncology at Narayana Health Bangalore, presenting 18-month clinical trial data on Qartemi, our CD-19 CAR T cell therapy approved for relapsed/refractory non-Hodgkin lymphoma. This critical data underscores the therapy's potential to provide new hope for patients battling aggressive blood cancers in India. Immuneel's commercial team was actively engaged throughout the conference, connecting with esteemed key opinion leaders (KOLs) from across the country. The scientific discussions and insights shared reinforced the importance of collaboration and innovation as we continue to pioneer accessible, high-quality CAR T therapies in India. We are grateful to Haematocon 2024 for providing an excellent platform to exchange knowledge and engage with the brightest minds in hematology. Immuneel remains committed to advancing our mission of enabling affordable, cutting-edge cell and gene therapies for Indian patients. #cellandgenetherapy #cancertreatment #Haematocon2024

Cutting edge technologies. Traditional values. Puja@Immuneel. At Immuneel, we believe in the power of tradition to bring people together and celebrate the values that drive us forward. This year, we marked the joyous occasion of Dussehra with great enthusiasm and the Ayudha Pooja at our facility was a moment of reflection and gratitude, as we sought blessings and divine guidance. This ceremony symbolizes our respect for the place of work that supports our mission in every step of our journey. Wishing everyone a prosperous and joyful Dussehra! Amit Mookim Lakshmikanth Gandikota Giri C Nitha Paul Rebu Ninan Akhil Agarwal Juthika C Anupam Chhabra, MD, MBA Yogananth Rajendran M.Pharm.RAC #DussehraCelebration #AyudhaPooja #TeamSpirit #WorkplaceCulture #ManufacturingExcellence #FestiveVibes #Gratitude #TogetherWeGrow

Reflecting on the Essence of the EHA Conference in Mumbai! Last week, the Immuneel team—Ms. Juthika C, Mr. Akhil Agarwal, Dr. Anupam Chhabra, MD, MBA, Mr. Rebu Ninan, and our CEO, Amit Mookim had the privilege of attending the prestigious Essence of EHA conference. A major highlight was the insightful presentation by Dr. sharat damodar, who shared our long-term clinical data on Qartemi (varnimcabtagene autoleucel), India's first commercially approved global CAR T cell therapy. Qartemi, approved for treating adult non-Hodgkin lymphoma (NHL), was in the spotlight as we revealed exciting new clinical data. The response was overwhelming, and we’re proud to see how this breakthrough therapy is gaining attention for its potential to address the unmet needs of patients with relapsed refractory B-NHL. It was a great opportunity to connect with experts from across the country and discuss the future of cancer care, especially in the realm of CAR T therapies. Thank you to everyone who contributed to making this event a success. We’re more motivated than ever to keep pushing the boundaries in cell and gene therapy! #EssenceofEHA #Qartemi #CARTTherapy #CellAndGeneTherapy #HealthcareInnovation #CancerResearch #Immuneel #ClinicalData

We’re #hiring.

Immuneel Therapeutics Welcomes Amit Mookim as CEO   We are excited to announce the appointment of Mr. Amit Mookim as the new Chief Executive Officer of Immuneel Therapeutics. Amit brings over 20 years of experience spanning life sciences, technology, and private equity, and we are confident that his vision and leadership will help drive our next phase of growth and impact in the cell and gene therapy space.   Amit joins us from IQVIA, where he successfully led South Asia as Managing Director, overseeing operations across 20,000+ professionals and significantly expanding the commercial business. Prior to IQVIA, Amit headed healthcare at KPMG India, where he built the practice from the ground up, working with hospitals, PE funds, and global healthcare companies to establish their presence in India. His contributions as an advisor to national bodies and industry organizations have made him a respected thought leader in healthcare strategy and market access. In the field of life sciences, he chipped in to guide the National Health Authority on creating market access for start-ups in PMJAY and has advised industry organizations such as the Indian Pharmaceutical Alliance, APACMED, OPPI, FICCI, and NATHEALTH on universal healthcare, market access, pricing, and innovation. Additionally, he has been involved in leadership committees and task forces to drive collaborative programs between industry and regulators. He possesses deep knowledge of commercializing new business models and expanding organizations and has worked across South Asia, APAC, the Middle East, Sub-Saharan Africa, and Europe.   Our co-founders, Dr. Kiran Mazumdar-Shaw, Dr. Siddhartha Mukherjee, and Dr. Kush Parmar have expressed their confidence that under Amit's leadership, Immuneel will continue to break new ground in cancer immunotherapy. As we move forward, Amit will focus on accelerating access to our CAR-T therapies, building global partnerships, and expanding our footprint across India and beyond.   Please join us in welcoming Amit to the Immuneel team as we continue our mission to transform cancer care for patients in India and beyond. Amit Mookim   #Leadership #Innovation #CellTherapy #GeneTherapy #Immunotherapy #CancerTreatment #Immuneel #CEO